Welcome to This Week in Clinical Trials. Every Monday, we share the most notable news in clinical trial results — what was tested, what was found, and what it means for patients. This is our edition for Monday, May 11, 2026.This week: Moderna's new mRNA flu shot cut confirmed flu cases by 27 percent in adults over 50 versus the standard flu vaccine, an experimental pill from Revolution Medicines shrank tumors in about a third of patients with advanced RAS-mutated pancreatic cancer, and a Danish trial found weekly semaglutide cut heavy drinking days for people with alcohol use disorder. You can find plain english summaries of all the latest completed trials at stellatrials.com/learn.Moderna announced this week that its mRNA flu shot beat the standard flu vaccine in older adults. The trial enrolled more than 40,000 adults aged 50 and over across one full flu season. Each person got either Moderna's new mRNA-1010 shot or a licensed standard-dose flu vaccine. Researchers then tracked who came down with flu over the season. Two percent of people who got the mRNA shot caught flu, compared with nearly three percent of those who got the standard shot. That works out to about 27 percent fewer confirmed flu cases in the mRNA group. Side effects were more common with the mRNA shot, including arm pain, fatigue, headache, and muscle aches. Most of those reactions were mild and went away within a few days. The trial was published in the New England Journal of Medicine. Moderna says it will take these results to regulators as it pursues approval.Now to pancreatic cancer. Revolution Medicines announced this week that an experimental pill called daraxonrasib showed promising activity against one of the deadliest cancers around. Pancreatic cancer is hard to catch early and even harder to treat once it spreads. More than nine in ten of these tumors carry a mutation in a gene called RAS. For decades, RAS was thought to be impossible to block with a drug. Daraxonrasib is a once-a-day pill designed to block several different RAS mutations at the same time. The trial included 168 patients with advanced pancreatic cancer who had already tried at least one earlier therapy. In a smaller group who got the dose chosen for the next stage of testing, tumors shrank in about 35 percent of people. Median overall survival in that group was around 13 months, much higher than what is usually seen at this stage. About one in three patients had serious side effects, including rash, diarrhea, and mouth sores. Results were published in the New England Journal of Medicine. The company is now moving daraxonrasib into a larger phase 3 study.Our last story comes from Denmark. Researchers at Rigshospitalet in Copenhagen tested a familiar drug for a new use. The drug is semaglutide, the same one sold as Ozempic and Wegovy for diabetes and weight loss. Their question: could it also help people cut back on alcohol? The trial included 108 adults who had both moderate or severe alcohol use disorder and obesity. Everyone got standard talk therapy. Half were also given a weekly injection of semaglutide at the dose used for weight loss. The other half got a placebo shot instead. After 26 weeks, heavy drinking days dropped by about 41 percentage points from baseline in the semaglutide group. In the placebo group, the drop was about 26 percentage points. Side effects were mostly the mild stomach issues people see with this drug class, like nausea. The trial was published in The Lancet. This was an early signal in a small study. The authors say much larger trials are needed before semaglutide could be used as a treatment for alcohol use disorder. Still, it adds to a growing pile of evidence that GLP-1 drugs may do more than control blood sugar and body weight.One quick reminder before we wrap. This show is news, not medical advice. Nothing we cover is meant to replace a conversation with your own doctor about your own care.That's this week in clinical trials. If any of these conditions affect you or someone you love, head to stellatrials.com — you can search for open trials matched to your situation, and follow the progress of trials as results come in. New episode every Monday. See you next week.